Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 58

Results For "Access"

2301 News Found

AstraZeneca to harmonise its listing structure across LSE, STO and NYSE
News | September 29, 2025

AstraZeneca to harmonise its listing structure across LSE, STO and NYSE

Harmonisation of listing structure requires a direct listing of AstraZeneca shares on the NYSE in place of existing US ADRs


Lilly opens biotech in San Diego
Startup | September 29, 2025

Lilly opens biotech in San Diego

82,514 sq ft facility to host up to 15 biotech companies, fueling the development of next-generation medicines


Infinitus launches MCP server to bring standardized AI interoperability to healthcare
Digitisation | September 29, 2025

Infinitus launches MCP server to bring standardized AI interoperability to healthcare

New infrastructure makes it possible for healthcare organizations to integrate AI agents seamlessly into critical workflows like benefit verification and prior authorization


FUJIFILM India installs DR X-ray system at CHC Dholera
News | September 26, 2025

FUJIFILM India installs DR X-ray system at CHC Dholera

The CSR initiative will offer Digital Radiology X-Ray service to Dholera and 33 surrounding villages in the region


Alkem launches pertuzumab biosimilar ‘Pertuza’ for treatment of HER2-positive breast cancer
News | September 24, 2025

Alkem launches pertuzumab biosimilar ‘Pertuza’ for treatment of HER2-positive breast cancer

Alkem's Pertuza is an affordable, indigenously-developed and manufactured biosimilar of pertuzumab


Merck & Siemens join forces to accelerate AI drug discovery and development
Digitisation | September 24, 2025

Merck & Siemens join forces to accelerate AI drug discovery and development

Merck and Siemens signed new MoU extending their strategic partnership to accelerate digital transformation in the life science industry


Glenmark signs cancer drug licensing deal with Hengrui Pharma for $18 million upfront payment
News | September 24, 2025

Glenmark signs cancer drug licensing deal with Hengrui Pharma for $18 million upfront payment

Hengrui is eligible to receive regulatory and commercial milestone payments of up to US$1.093 billion


Eli Lilly to build new $6.5 billion orforglipron manufacturing facility in Texas
News | September 24, 2025

Eli Lilly to build new $6.5 billion orforglipron manufacturing facility in Texas

The new Houston site, Lilly's eighth U.S. manufacturing facility announced since 2020, will focus on domestic production of small molecule synthetic medicines